Regeneron Pharmaceuticals (REGN) Operating Margin (2009 - 2026)

Regeneron Pharmaceuticals' Operating Margin history runs 18 years deep, the most recent figure standing at 30.15% for Q2 2026.

• In Q2 2026, Operating Margin rose 78.0% year-over-year to 30.15%; the TTM figure through Jun 2026 stood at 24.74% (down 228.0% YoY), while the FY2025 annual figure was 24.95%, down 315.0% from the prior year.
• Operating Margin for Q2 2026 stood at 30.15%, up from 17.83% in the prior quarter.
• The five-year high for Operating Margin was 2517.0% in Q1 2022, with the low at 17.83% in Q1 2026.
• The 5-year median for Operating Margin is 30.04% (2023), against an average of 229.25%.
• The sharpest annual moves came in 2022 and 2023: Operating Margin soared 247300 bps in 2022, then plunged 248706 bps in 2023.
• Regeneron Pharmaceuticals' Operating Margin stood at 1146.8% in 2022, then tumbled by 98 bps to 28.33% in 2023, then decreased by 8 bps to 26.13% in 2024, then retreated by 13 bps to 22.65% in 2025, then surged by 33 bps to 30.15% in 2026.
• Business Quant data shows REGN's Operating Margin at 30.15% in Q2 2026, 17.83% in Q1 2026, and 22.65% in Q4 2025.